US and UK Strike Three-Year Zero-Tariff Deal on British Medicines
London agrees to boost NHS drug spending in return for Washington exempting UK pharmaceutical exports from import taxes
The United States and United Kingdom have agreed that British-made pharmaceuticals, medical-device components and drug ingredients will enter the U.S. market free of tariffs for the next three years.
The accord follows repeated threats from the U.S. to impose steep import levies on foreign medicines and forms part of a broader trade framework negotiated this year under U.S. President Donald Trump and UK Prime Minister Keir Starmer.
As part of the deal, Britain will increase domestic spending on medicines: the threshold for approving cost-effective new treatments will rise by 25 per cent and the rebate drug companies pay back to the public health service on overspending will be capped at 15 per cent.
The British health service will also commit to raising its overall medicine budget share — potentially doubling the current portion of GDP devoted to pharmaceuticals over the coming decade.
UK officials have hailed the agreement as vital for protecting an export sector worth some £11 billion a year and safeguarding thousands of jobs while strengthening Britain’s life-sciences industry.
The zero-tariff guarantee is intended to undercut the punitive import taxes previously threatened under U.S. Section 232 trade measures.
For patients and the public health system, ministers argue the deal will ease barriers to cutting-edge treatments — including therapies for cancer and rare diseases — that had previously been turned down purely on cost-effectiveness grounds under the old assessment framework.
Estimates suggest the new pricing rules could lead to the approval of between three and five additional medicines each year.
However, the pact has sparked concern from some political opponents and health-service leaders who caution the additional drug costs — potentially running to several billion pounds annually — will place fresh strain on public finances.
They argue expanding medicine spending may divert resources from core services such as hospitals, general practitioners and routine care.
Drug-industry leaders welcomed the agreement as a signal that Britain remains competitive as a global hub for innovation, manufacturing and export in pharmaceuticals, offering certainty to firms that had previously paused or scaled back UK investment amid tariff threats and pricing pressures.
Industry proponents argue the stability provided by the tariff exemption will help attract renewed research, development and manufacturing activity across the UK life-sciences sector.
The accord follows repeated threats from the U.S. to impose steep import levies on foreign medicines and forms part of a broader trade framework negotiated this year under U.S. President Donald Trump and UK Prime Minister Keir Starmer.
As part of the deal, Britain will increase domestic spending on medicines: the threshold for approving cost-effective new treatments will rise by 25 per cent and the rebate drug companies pay back to the public health service on overspending will be capped at 15 per cent.
The British health service will also commit to raising its overall medicine budget share — potentially doubling the current portion of GDP devoted to pharmaceuticals over the coming decade.
UK officials have hailed the agreement as vital for protecting an export sector worth some £11 billion a year and safeguarding thousands of jobs while strengthening Britain’s life-sciences industry.
The zero-tariff guarantee is intended to undercut the punitive import taxes previously threatened under U.S. Section 232 trade measures.
For patients and the public health system, ministers argue the deal will ease barriers to cutting-edge treatments — including therapies for cancer and rare diseases — that had previously been turned down purely on cost-effectiveness grounds under the old assessment framework.
Estimates suggest the new pricing rules could lead to the approval of between three and five additional medicines each year.
However, the pact has sparked concern from some political opponents and health-service leaders who caution the additional drug costs — potentially running to several billion pounds annually — will place fresh strain on public finances.
They argue expanding medicine spending may divert resources from core services such as hospitals, general practitioners and routine care.
Drug-industry leaders welcomed the agreement as a signal that Britain remains competitive as a global hub for innovation, manufacturing and export in pharmaceuticals, offering certainty to firms that had previously paused or scaled back UK investment amid tariff threats and pricing pressures.
Industry proponents argue the stability provided by the tariff exemption will help attract renewed research, development and manufacturing activity across the UK life-sciences sector.
